AR053477A1 - Cartamo con acido gamma - linolenico elevado - Google Patents

Cartamo con acido gamma - linolenico elevado

Info

Publication number
AR053477A1
AR053477A1 ARP060102090A ARP060102090A AR053477A1 AR 053477 A1 AR053477 A1 AR 053477A1 AR P060102090 A ARP060102090 A AR P060102090A AR P060102090 A ARP060102090 A AR P060102090A AR 053477 A1 AR053477 A1 AR 053477A1
Authority
AR
Argentina
Prior art keywords
seeds
safflower
gla
sequences
linolenic
Prior art date
Application number
ARP060102090A
Other languages
English (en)
Original Assignee
Arcadia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcadia Biosciences Inc filed Critical Arcadia Biosciences Inc
Publication of AR053477A1 publication Critical patent/AR053477A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition

Abstract

La presente se refiere a composiciones y métodos para preparar ácido gamma-linoleico (GLA) en plantas de cártamo, particularmente de semillas de cártamo. Las secuencias de ácidos nucleicos y construcciones que codifican una o más secuencias de desaturasas de ácidos grasos se utilizan para generar plantas de cártamo transgénicas que contienen y expresan una o más de estas secuencias y producen altos niveles de GLA en semillas de cártamo. Se proporcionan plantas de cártamo transgénicas y semillas que producen altos niveles de GLA. Se proporcionan además aceites producidos de semillas de la presente. La presente también se refiere a métodos de tratamiento de una variedad de enfermedades incluyendo trastornos del sistema nervioso, afecciones inflamatorias, cáncer y trastornos cardiovasculares utilizando los aceites de la presente.
ARP060102090A 2005-05-23 2006-05-22 Cartamo con acido gamma - linolenico elevado AR053477A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68413405P 2005-05-23 2005-05-23
US73598405P 2005-11-10 2005-11-10

Publications (1)

Publication Number Publication Date
AR053477A1 true AR053477A1 (es) 2007-05-09

Family

ID=37452775

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102090A AR053477A1 (es) 2005-05-23 2006-05-22 Cartamo con acido gamma - linolenico elevado

Country Status (13)

Country Link
US (2) US7893321B2 (es)
EP (1) EP1885862B1 (es)
JP (1) JP5033122B2 (es)
CN (1) CN101321872B (es)
AR (1) AR053477A1 (es)
AU (1) AU2006249983B2 (es)
BR (1) BRPI0611480B1 (es)
CA (1) CA2609367C (es)
CL (1) CL2007003413A1 (es)
ES (1) ES2550623T3 (es)
HK (1) HK1120823A1 (es)
NZ (1) NZ563676A (es)
WO (1) WO2006127789A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519724A2 (pt) * 2004-12-20 2009-01-20 Basf Plant Science Gmbh polipeptÍdeo isolado, seqÜÊncia de Ácido nucleico isolada, Ácido nucleico isolado, vetor de expressço, mÉtodos de produzir uma planta transgÊnica e de modular o nÍvel de uma porcentagem em peso de composto de armazenagem de semente em uma planta, planta transgÊncia, e, semente
CN101516181B (zh) 2006-07-14 2015-09-30 联邦科学技术研究组织 改变水稻的脂肪酸组成
EP2271223A2 (de) * 2008-04-25 2011-01-12 BASF Plant Science GmbH Pflanzensamenöl
US8148121B2 (en) * 2008-08-01 2012-04-03 E.I. Du Pont De Nemours And Company Δ6 desaturases and their use in making polyunsaturated fatty acids
NZ631696A (en) * 2012-04-25 2017-02-24 Grains Res & Dev Corp High oleic acid oils
PL2861059T3 (pl) 2012-06-15 2017-10-31 Commw Scient Ind Res Org Wytwarzanie długołańcuchowych wielonienasyconych kwasów tłuszczowych w komórkach roślinnych
CA2932654A1 (en) 2013-12-10 2015-06-18 The University Of York Desaturase nucleic acids and polypeptides
NZ721036A (en) 2013-12-18 2023-07-28 Grains Res & Dev Corp Lipid comprising long chain polyunsaturated fatty acids
SG11201610596PA (en) 2014-06-27 2017-01-27 Commw Scient Ind Res Org Lipid comprising docosapentaenoic acid

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034322A (en) 1983-01-17 1991-07-23 Monsanto Company Chimeric genes suitable for expression in plant cells
US4743548A (en) 1984-09-25 1988-05-10 Calgene, Inc. Plant cell microinjection technique
US5420034A (en) 1986-07-31 1995-05-30 Calgene, Inc. Seed-specific transcriptional regulation
US4943674A (en) 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
US5068193A (en) 1985-11-06 1991-11-26 Calgene, Inc. Novel method and compositions for introducing alien DNA in vivo
US4795855A (en) 1985-11-14 1989-01-03 Joanne Fillatti Transformation and foreign gene expression with woody species
US5188958A (en) 1986-05-29 1993-02-23 Calgene, Inc. Transformation and foreign gene expression in brassica species
US5565347A (en) 1986-06-10 1996-10-15 Calgene, Inc. Transformation and foreign gene expression with plant species
DE3856589D1 (de) 1987-10-20 2006-04-06 Bayer Bioscience Nv 5'-flankierende Region eines Genes von Arabidopsis, das für einen 2S Albumin-Prekursor kodiert
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5565346A (en) 1988-07-27 1996-10-15 Calgene, Inc. Transformation and regeneration system for legumes
US5106739A (en) 1989-04-18 1992-04-21 Calgene, Inc. CaMv 355 enhanced mannopine synthase promoter and method for using same
US5175095A (en) 1989-07-19 1992-12-29 Calgene, Inc. Ovary-tissue transcriptional factors
ES2033193B1 (es) 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
US6355861B1 (en) 1991-10-10 2002-03-12 Rhone-Poulenc Agrochimie Production of gamma linolenic acid by a Δ6-desaturase
US5614393A (en) 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
PH31293A (en) 1991-10-10 1998-07-06 Rhone Poulenc Agrochimie Production of y-linolenic acid by a delta6-desaturage.
ES2187505T3 (es) 1992-04-02 2003-06-16 Sembiosys Genetics Inc Elementos cis de proteinas de cuerpo oleoso como señales reguladoras.
US5539092A (en) 1992-10-02 1996-07-23 Arch Development Corporation Cyanobacterial and plant acetyl-CoA carboxylase
JPH08509860A (ja) 1993-02-26 1996-10-22 カルジーン インコーポレイティド ジェミニウィルスを基礎とする遺伝子発現系
US6432684B1 (en) 1997-04-11 2002-08-13 Abbott Laboratories Human desaturase gene and uses thereof
IL132148A0 (en) 1997-04-11 2001-03-19 Calgene Llc Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
US6051754A (en) 1997-04-11 2000-04-18 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
US6075183A (en) 1997-04-11 2000-06-13 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
US5968809A (en) 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
US5972664A (en) 1997-04-11 1999-10-26 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
TR199902583T2 (xx) * 1997-04-15 2000-05-22 Commonwealth Scientific And Industrial Research Bitki ya� asidi epoksijenaz genleri ve kullan�mlar�.
EP1019517B2 (en) 1997-09-30 2014-05-21 The Regents of The University of California Production of proteins in plant seeds
US6653530B1 (en) * 1998-02-13 2003-11-25 Calgene Llc Methods for producing carotenoid compounds, tocopherol compounds, and specialty oils in plant seeds
US6492108B1 (en) 1998-03-26 2002-12-10 Incyte Genomics, Inc. Delta-6 desaturase homologs
WO1999064614A2 (en) 1998-06-12 1999-12-16 Calgene Llc Polyunsaturated fatty acids in plants
US6677145B2 (en) * 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
US6403349B1 (en) * 1998-09-02 2002-06-11 Abbott Laboratories Elongase gene and uses thereof
US6342657B1 (en) 1999-05-06 2002-01-29 Rhone-Poulenc Agro Seed specific promoters
CA2376383C (en) * 1999-06-07 2009-11-17 Basf Plant Science Gmbh .delta.6-acetylenase and .delta.6-desaturase from ceratodon purpureus
US6815579B1 (en) * 1999-07-22 2004-11-09 The University Of British Columbia Plant long chain fatty acid biosynthetic enzyme
US6777591B1 (en) 1999-08-27 2004-08-17 Sembiosys Genetics Inc. Legume-like storage protein promoter isolated from flax and methods of expressing proteins in plant seeds using the promoter
KR20020073580A (ko) * 2000-02-09 2002-09-27 바스프 악티엔게젤샤프트 신규 연장효소 유전자 및 다가불포화 지방산의 제조 방법
DE10102337A1 (de) * 2001-01-19 2002-07-25 Basf Plant Science Gmbh Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren, neue Biosynthesegene sowie neue pflanzliche Expressionskonstrukte
BR0205508A (pt) 2001-01-25 2005-05-03 Abbott Lab Genes para dessaturase e usos dos mesmos
US6635451B2 (en) 2001-01-25 2003-10-21 Abbott Laboratories Desaturase genes and uses thereof
PT1440151E (pt) * 2001-09-05 2008-03-17 Monsanto Technology Llc Promotor 7s alfa específico da semente para expressar genes em plantas
BRPI0411479A (pt) 2003-06-17 2006-07-25 Sembiosys Genetics Inc métodos para a produção de insulina em plantas
JP5031366B2 (ja) * 2003-08-01 2012-09-19 ビーエーエスエフ プラント サイエンス ゲーエムベーハー トランスジェニック生物における多不飽和脂肪酸の製造方法

Also Published As

Publication number Publication date
WO2006127789A3 (en) 2007-11-29
CA2609367A1 (en) 2006-11-30
WO2006127789A2 (en) 2006-11-30
CL2007003413A1 (es) 2008-07-25
EP1885862A4 (en) 2009-02-25
EP1885862B1 (en) 2015-07-29
US8192964B2 (en) 2012-06-05
AU2006249983A1 (en) 2006-11-30
CN101321872B (zh) 2012-09-05
BRPI0611480B1 (pt) 2016-06-07
ES2550623T3 (es) 2015-11-11
WO2006127789A9 (en) 2012-03-01
CN101321872A (zh) 2008-12-10
US20110129428A1 (en) 2011-06-02
HK1120823A1 (en) 2009-04-09
JP2008545411A (ja) 2008-12-18
JP5033122B2 (ja) 2012-09-26
EP1885862A2 (en) 2008-02-13
NZ563676A (en) 2011-01-28
US20070067870A1 (en) 2007-03-22
US7893321B2 (en) 2011-02-22
BRPI0611480A2 (pt) 2010-09-14
AU2006249983B2 (en) 2011-03-17
CA2609367C (en) 2014-08-19

Similar Documents

Publication Publication Date Title
AR053477A1 (es) Cartamo con acido gamma - linolenico elevado
CL2017000465A1 (es) Generación de plantas haploides
AR103446A1 (es) Método para modificar con precisión una planta a través de la expresión transitoria de genes
CL2018002140A1 (es) Métodos y composiciones para aumentar la eficiencia de modificación genética dirigida usando reparación genética mediada por oligonucleótidos
AR051495A1 (es) Promotor de l gen cr1bio de maiz y su uso para dirigir la expresion transgenica con preferencia por las raices en plantas
BR112015023378A2 (pt) métodos de modular sementes de plantas e conteúdo nectário
AR059650A1 (es) Plantas que presentan aumento en el rendimiento y metodo para lograrlo
AR076273A1 (es) Genes vegetales de la proteina quinasa relacionados con el gen sfn-1
AR105760A1 (es) Métodos y constructos para la modificación específica de ácidos nucleicos en plantas
AR052061A1 (es) Moleculas de acido nucleico que codifican genes de desaturasa de acidos grasos de plantas y metodos de uso
AR053279A1 (es) Regulacion post-transcripcional de la expresion genica
CO2018001264A2 (es) Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos
UY36909A (es) Promotor y 3’ utr de plantas para la expresión del transgén
AR114072A1 (es) Plantas con genes dhs modificados
CL2015000016A1 (es) Plantas brassica con composición de aceite de semilla modificada
UY37295A (es) Promotor vegetal y 3’ utr para la expresión de transgenes
AR052203A1 (es) Nuevos miembros de la familia de desaturasa de acido graso omega - 3 y usos de estos
AR075126A1 (es) Metodo para el mejor uso del potencial de produccion de plantas transgenicas
AR072157A1 (es) Metodos y medios para aumentar la eficacia en el uso de agua en plantas
AR068542A1 (es) Plantas que tienen biomasa aumentada
AR120136A1 (es) Plantas modificadas que comprende una mutación en una secuencia de ácido nucleico lazy4
EA201991714A1 (ru) Регуляторные элементы растений и их использование
AR096230A1 (es) Composiciones y métodos para implementar una mezcla de semillas transgénicas de refugio
UY36908A (es) Promotor y 3’ utr de plantas para la expresión del transgén
CL2007003531A1 (es) Metodo de produccion de planta transgenica que comprende alterar el nivel del producto de al menos un gen que se expresa especificamente durante las fases de formacion de la madera; construccion de adn; celula vegetal transformada con dicha construccion.

Legal Events

Date Code Title Description
FG Grant, registration